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Abstract
Background: Increased plasma concentration of N-terminal-prohormone B-type
natriuretic peptide (NT-proBNP) can be detected in cats with cardiac disease. Poten-
tial effects of feline characteristics on NT-proBNP concentration may influence clini-
cal usefulness.
Objectives: To evaluate potential effects of feline characteristics on NT-proBNP
plasma concentration and to compare NT-proBNP plasma concentrations in healthy
cats with results in hypertrophic cardiomyopathy (HCM) cats with or without left
atrial enlargement (LAE) using an ELISA and a point-of-care test (POCT), and assess if
POCT results reflect ELISA results.
Animals: One hundred healthy cats of 3 breeds and 39 HCM cats were included.
Methods: Diseases other than HCM were excluded by physical examination, blood
pressure measurement, echocardiography, hematology, and serum biochemistry.
Results: Higher NT-proBNP concentrations were found in males than in females in
healthy (P = .005) and in HCM cats (P = .0021), but breed had no effect on NT-
proBNP concentrations. Using ≥100 pmol/L as a cutoff for abnormal samples, ELISA
and POCT had similar sensitivity (SE; 72 and 74%) and specificity (SP; 97 and 98%)
for detecting cats with HCM, cats with HCM and LAE (SE, both 100%; SP, 97 versus
98%), and cats with HCM without LAE (SE, both 69%; SP, 97 versus 98%), respec-
tively, when compared to healthy cats.
Conclusions and Clinical Importance: Breed had no effect on plasma NT-proBNP
concentrations, but higher concentrations were found in male than in female cats.
Abbreviations: 2D, 2-dimension; ALT, alanine aminotransferase; Ao, aorta; BCS, body condition score; BNP, B-type natriuretic peptide; BW, body weight; CHF, congestive heart failure; CV,
coefficient of variation; DSH, Domestic Shorthair; FS, fractional shortening; HCM, hypertrophic cardiomyopathy; HDO, high-definition oscillometric device; HR, heart rate auscultation; IQR,
interquartile range; IVSd, interventricular septum diastole; IVSdinc%, percentage increase interventricular septal diameter in end diastole; LA, left atrium; LA/Ao, left atrial-to-aortic root diameter
ratio; LV, left ventricle; LVFWd, left ventricular free wall diameter in end diastole; LVFWdinc%, percentage increase of left ventricular free wall diameter in end diastole; LVIDd, left ventricular
internal diameter in end diastole; LVIDdinc%, percentage increase of left ventricular internal diameter in end diastole; LVIDs, left ventricular internal diameter in systole; NF, Norwegian Forest;
NP, natriuretic peptide; NT-proBNP, N-terminal-prohormone-B-type natriuretic peptide; proBNP, prohormone-BNP; POCT, point-of-care test; ROC, receiver operator characteristic curve; SAM,
systolic anterior motion; SBP, systolic blood pressure; SE, sensitivity; SP, specificity; T4, thyroxine.
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The ELISA and POCT had similar SE and SP for detecting HCM. Both tests could
identify all HCM cats with LAE but not all HCM cats without LAE.
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1 | INTRODUCTION
A high prevalence of cardiac disease has been reported in cats, and
affected individuals may develop severe dyspnea because of conges-
tive heart failure (CHF), as well as arterial thromboembolism and sud-
den death.1,2 Hypertrophic cardiomyopathy (HCM) is the most
common cardiac disease in cats,3,4 and this form of cardiomyopathy is
characterized by hypertrophy of the left ventricle (LV).5 Cardiac dis-
ease remains preclinical in many affected cats, and suspicion of car-
diac disease may occur when the clinician incidentally discovers a
murmur, gallop sound, or arrhythmia.3,4,6
Cardiac biomarkers in blood samples may be measured as part of
clinical assessment, especially when echocardiography is not available.
B-type natriuretic peptide (BNP) is produced as prohormone-BNP
(proBNP) by cardiomyocytes in response to wall stretch.7 Inactive
proBNP is cleaved intracellularly before release from the car-
diomyocyte into biologically active BNP, which has a short half-life,
and inactive more stable N-terminal-proBNP (NT-proBNP), which
usually is measured in clinical settings.8
A quantitative ELISA that measures NT-proBNP concentration is
available for cats, as is a semiquantitative point-of-care test
(POCT).9,10 The ELISA test is offered by a commercial laboratory
(IDEXX Laboratories Inc, Westbrook, Maine), whereas the POCT
offers a quick assessment of NT-proBNP concentration in the clinic.
The POCT assay results are normal or abnormal based on a cutoff NT-
proBNP concentration of approximately 100 pmol/L according to the
manufacturer (SNAP Feline proBNP, IDEXX Laboratories Inc).
The transition interval when the POCT becomes positive has been
reported to range between 108 and 200 pmol/L.9,11 Abnormal ELISA
or POCT NT-proBNP results in cats have been shown to be associ-
ated with cardiac disease, implying that further diagnostic evaluation
by echocardiography is indicated.5,9-14 Previous studies have reported
that both quantitative and semiquantitative NT-proBNP concentra-
tions can discriminate cats with cardiac disease from healthy cats.
Sensitivity (SE) has been described to vary between 65.4 and 93.9%,
and specificity (SP) between 87.8 and 100%.9-12,14,15 These studies
included cats with various cardiac diseases.
In dogs, considerable interbreed variation exists in concentration
of NT-proBNP.16-19 Studies specifically designed to investigate breed
variation in NT-proBNP concentration in cats have not been per-
formed previously. In 1 study designed to investigate NT-proBNP
concentration in cats with HCM of different severity, breed had no
influence on NT-proBNP concentration.14 In that study, several
breeds were included, often comprising only a few cats per breed.14
Furthermore, little information is available concerning other
characteristics such as sex, age and body condition score (BCS) on
plasma NT-proBNP concentration.12,14,20
We hypothesized that plasma concentrations of NT-proBNP
(1) vary with characteristics such as breed, sex, age, body weight
(BW) and BCS; (2) may differentiate cats with HCM with or without
left atrial enlargement (LAE) from healthy cats; and (3) POCT results
reflect ELISA results. Our aims were to assess potential effects of
feline characteristics on NT-proBNP plasma concentration, to com-
pare NT-proBNP concentrations in healthy cats with concentrations
in HCM cats with or without LAE using ELISA and a POCT, and to
assess if POCT results reflect ELISA results.
2 | MATERIALS AND METHODS
2.1 | Recruitment
The study was approved by the Uppsala Animal Experiment Ethics
Board. Cats were recruited prospectively to participate in the study
through information for cat owners provided on webpages, at semi-
nars or at the recruiting clinic. Client-owned cats were examined at
Evidensia Animal Clinic in Västerås between September 2014 and
June 2017. Clinically healthy cats and cats with murmurs or previously
diagnosed HCM were examined for possible inclusion in the study.
Informed written consent was obtained from the owner of each cat.
2.2 | Inclusion criteria
Healthy cats of nonpurebred Domestic Shorthair (DSH), purebred Bir-
man and Norwegian Forest (NF), and HCM cats of any breed were
allowed into the study. Cats with preclinical or clinical HCM, stabilized
as a consequence of CHF treatment, were allowed into the study.
Cats aged between 1 and 14 years were eligible for the study.
All healthy cats must have had normal echocardiogram. Diagnosis of
HCM was based on characteristic findings on an echocardiogram as
outlined below.21-23
2.3 | Exclusion criteria
Cats with increased mean systolic blood pressure (SBP) >160 mmHg,
increased serum concentrations of thyroxine (TT4), creatinine, or fruc-
tosamine, increased alanine aminotransferase (ALT) activity, or some
combination of these were excluded from the study. Cats with
1188 HANÅS ET AL.
decompensated CHF, thromboembolism, congenital cardiac disease,
other acquired cardiovascular disorders, equivocal findings concerning
the presence of hypertrophy of the LV, severe dental disease or clini-
cally relevant organ-related or systemic diseases were not included in
the study. All cats receiving medical treatment other than those in
need of standard CHF treatment, standard antithrombotic treatment,
medroxyprogesterone acetate, or deslorelin acetate were excluded
from the study.
2.4 | Clinical examination and blood pressure
measurement
All examinations were performed according to a standardized protocol in
a quiet examination room by a single experienced veterinarian (S.H.). The
healthy control cats were examined between 0900 and 1300 hours. The
cats were allowed to adapt to the environment for 10-15 minutes
together with their owners before SBP measurement.24 An appropriate
cuff was applied to the base of the tail and the cats then were allowed
to rest in their carrier before SBP was indirectly measured using an auto-
mated high-definition oscillometric (HDO) device (VET Memodiagnostic
HDOmonitor, S+B medVET, Babenhausen, Germany).25 Once consistent
consecutive readings were obtained, 6 recordings were performed. Mean
values for SBP were determined for each cat, after discarding recordings
deviating more than 20%.24
After the SBP measurement, all cats underwent general physical
examination. The BCS was recorded on a 9-point scale.26
2.5 | Echocardiography
Transthoracic 2-dimensional (2D), M-mode, color flow, and spectral
Doppler echocardiographic evaluations were performed by an experi-
enced echocardiographer, trained by a board-certified veterinary car-
diologist, in unsedated cats placed first in right and then in left lateral
recumbency using an ultrasound system (IE33, Philips Ultrasound,
Bothell, Washington) equipped with a 4-12 MHz phased-array probe.
Continuous electrocardiography monitoring was performed during
echocardiographic examination. Images and loops from standardized
imaging planes21 were stored digitally. The left atrial-to-aortic root
diameter ratio (LA/Ao) was measured in 2D from the right 2D short-
axis view.22 Diastolic and systolic LV dimensions (interventricular sep-
tum diastole [IVSd], LV internal diameter in end diastole [LVIDd], LV
free wall diameter in end diastole [LVFWd], LV internal diameter in
systole [LVIDs], and fractional shortening [FS]) were measured from
M-mode and 2D using right parasternal short- and long-axis
images.21,23 Mitral, tricuspid, aortic, and pulmonic valves were interro-
gated using spectral and color-flow Doppler according to published
recommendations.21,23 Two-dimensional images of the LV outflow
tract were used to identify the presence of systolic anterior motion
(SAM) of the mitral valve.
The diagnosis HCM was made when a subjective impression of
hypertrophy (regional or global) was supported by increased M-mode
and 2D diastolic LV wall dimensions of the interventricular septum
(IVSd), left ventricular free wall (LVFWd), or both defined as outlined
below. Left atrial size was assessed using the LA/Ao as previously
described.22 Expected BW-dependent values for IVSd, LVIDd, and
LVFWd were calculated according to previously generated formulas
for cats.27 Percentage deviation from these expected values was cal-
culated according to the formula: Xinc(%) = ([observed value-expected
value]/expected value) × 100, where X represents the variable in
question. These calculated percentage deviations from expected BW-
dependent values,27 and the LA/Ao ratio were used to classify the
cats into 3 different groups: healthy controls, HCM without LAE, and
HCM with LAE. Cats with subjectively normal LV morphology, LA/Ao
<1.5,27,28 and <30% increase in BW-based predicted values for IVSd
and LVFWd27 were classified as healthy cats. Cats with subjective
impression of LV hypertrophy and ≥30% increase in BW-based
predicted values for IVSd or LVFWd were classified as having HCM
without LAE if LA/Ao <1.5, and with LAE if LA/Ao ≥1.5. Cats that
could not be classified according to the criteria specified above were
excluded from the study.
2.6 | Blood collection and analysis
Blood was collected in ethylenediaminetetraacetic acid (EDTA) and
serum tubes by venipuncture of the cephalic vein in unsedated mini-
mally restrained cats. Hematology and serum biochemistry profiles,
including ALT activity, creatinine, glucose, and total protein concen-
trations, were performed at Evidensia Animal Clinic in Västerås imme-
diately after sampling using the ProCyte (IDEXX ProCyte Dx, IDEXX
Laboratories, Inc) and Catalyst (Catalyst Dx Chemistry Analyzer,
IDEXX Laboratories, Inc) systems. Total thyroxine and fructosamine
concentrations were analyzed within a few days after each sampling
at the Clinical Pathology Laboratory of the University Animal Hospital,
Swedish University of Agricultural Sciences using the Immulite
(IMMULITE 2000, Siemens Healthcare GmbH, Erlangen, Germany)
and Abbott Architect (Abbott Architect c4000, Abbott Park, IL, USA)
systems.
For later analysis of NT-proBNP, EDTA blood was centrifuged
and plasma frozen at −80C within 30 minutes of collection for stor-
age. All samples were transported frozen (−80C) to a commercial lab-
oratory (Vet Med Labor GmbH, Division of IDEXX Laboratories,
Ludwigsburg, Germany) for batch analysis in duplicate using a vali-
dated second-generation ELISA for cats (CardioPet NT-proBNP assay,
IDEXX Laboratories, Inc).29 The reported assay range for NT-proBNP
concentration at the commercial laboratory was 24-1500 pmol/L. For
statistical analyses, concentrations of NT-proBNP less than the lowest
reported concentration were assigned a result of 24 pmol/L. Concen-
trations of NT-proBNP >1500 pmol/L were assigned a result of
1500 pmol/L.
All samples also were analyzed using the POCT feline NT-proBNP
(SNAP Feline proBNP, IDEXX Laboratories Inc) according to the
instructions of the manufacturer. The samples were randomized and
the examiner (S.H.) performing the evaluation of the POCT was
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blinded to the identity of the cats. Plasma was thawed and kept at
room temperature for <30 minutes before analysis. Normal results
were recorded when the density of the sample spot appeared lighter
than the reference spot, according to the manufacturer's instructions
(IDEXX Reference Laboratories Inc). Abnormal results were recorded
when the density of the sample spot appeared equal to or darker than
the reference spot, which, according to the manufacturer, occurs when
concentrations are >100 pmol/L (IDEXX Reference Laboratories Inc).
Evaluation of the POCT was performed on the same occasion by visual
inspection and using an automated evaluation (SNAP Pro Analyzer,
IDEXX Laboratories Inc). The examiner performed the visual inspection
before checking and documenting the results from the automated
evaluation. Visual inspection of the POCT results was classified into
3 groups (lighter, equal, and darker), based on subjective evaluation of
the sample spot color. After all samples had been analyzed, concentra-
tions of NT-proBNP measured by ELISA were revealed.
2.7 | Statistical analysis
Statistical analyses were performed using a commercially available
software program (JMP, version 12.2.0, SAS Institute Inc, Cary, North
Carolina). Group data are presented as medians and interquartile
range (IQR). A value of P < .05 was considered significant, unless oth-
erwise indicated.
Univariable analyses were performed separately in 3 groups of cats:
all cats, healthy cats and HCM cats. Fisher's exact test was used for com-
paring proportions. The nonparametric Kruskal-Wallis test was used to
evaluate the effects of nominal and ordinal variables (sex, neutered or
intact, BCS, presence or absence of SAM) on NT-proBNP concentra-
tions. Furthermore, the Kruskal-Wallis test was used to evaluate the
overall association between the POCT results (intensity of color in the
POCT) and the plasma NT-proBNP concentrations in all cats, and for
evaluating the effect of breed in the healthy cat group. The Kruskal-
Wallis test was used followed by Bonferroni correction for post hoc
comparison between groups. These statistical analyses were repeated in
the HCM cats after excluding 6 cats treated with cardiac medications
(furosemide, enalapril, clopidogrel).
Spearman's ρ was used to evaluate potential associations
between plasma NT-proBNP concentration and continuous variables
(age, SBP, heart rate auscultation [HR] obtained from clinical examina-
tion, echocardiographic measurements, and storage time of the
plasma samples) for any of the cat groups with a high rate of non-
detectable NT-proBNP plasma concentrations.
TABLE 1 Feline characteristics, echocardiographic and laboratory variables in 139 cats with and without hypertrophic cardiomyopathy
Healthy HCM without LAE HCM with LAE
Number 100 32 7
Sex (F/M) 57/43 12/20 1/6
Sex NF/F/NM/M 35/22/33/10 9/3/16/4 0/1/6/0
Age (years) 4.6 (2.1-8.7)a 5.3 (3.6-9.1)a 6.6 (3.0-9.0)a
Weight (kg) 4.3 (3.6-5.5)a 5.0 (4.1-5.9)a 5.1 (3.8-5.9)a
BCS normal 4-5/overweight 6-7) 49/501 6/224 5/2
HR (bpm) 160 (140-180)a 160 (143-200)a 180 (150-200)a
Murmur (yes/no) 4/96 30/2 7/0
SBP (mmHg) 135 (123-143)a 140 (131-148)a 130 (128-134)a
LA/Ao 1.1 (1.0-1.2)a 1.1 (1.0-1.2)a 1.6 (1.6-1.7)b
IVSd (mm) 3.8 (3.5-4.1)a 6.1 (5.3-6.4)b 6.8 (6.5-8.5)b
IVSd inc (%) −0.6 (−6.3 to 5.8)a 52.7 (44.4-68.7)b 83.0 (63.5-114.6)c
LVIDd (mm) 15.9 (14.9-17.4)a 15.0 (13.2-16.5)b 14.7 (14.0-17.6)ab
LVIDdinc (%) 1.1 (−4.8 to 8.3)a −5.6 (−18.4 to −2.1)b −10.2 (−14.5 to 15.7)ab
LVFWd (mm) 3.7 (3.5-4.0)a 5.3 (4.4-6.2)b 7.7 (7.1-8.1)c
LVFWdinc (%) −0.9 (−6.3 to 4.6)a 31.7 (14.8-58.1)b 105.3 (89.6-114.0)c
FS (%) 50 (46-56)a 60 (52-64)b 47 (41-59)ab
SAM (yes/no) 0/100 24/8 5/2
Note: Within each row, values with different letter superscripts are statistically different (P < .017) after Bonferroni correction, and values with the same
superscript letter did not differ significantly. For description of the grading of hypertrophic cardiomyopathy, see the main text. Superscript numbers for
specific comment for number of missing values: 1 = one missing value, 3 = three missing values, 4 = four missing values. The median and interquartile
ranges are shown for continuous variables.
Abbreviations: BCS, body condition score; F, female; FS, fractional shortening; HCM, hypertrophic cardiomyopathy; IVSd, interventricular septum diastole;
IVSdinc%, percentage increase in end-diastolic interventricular septal dimension; LA/Ao, left atrial-to-aortic root diameter ratio; LAE, left atrial enlargement;
LVFWd, left ventricular free wall diameter in end diastole; LVFWdinc%, percentage increase in end-diastolic left ventricular free wall dimension; LVIDd, left
ventricular internal diameter in end diastole; LVIDdinc%, percentage increase in end-diastolic left ventricular internal dimension; M, male; N, neutered; HR,
heart rate auscultation; SAM, systolic anterior motion of the mitral valve; SBP, systolic blood pressure, basic echocardiographic data.
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After logarithmic transformation of the concentration of NT-
proBNP, linear regression was used to evaluate potential associations
between plasma NT-proBNP concentration and continuous variables
(age, BW, SBP, echocardiographic measurements, HR obtained from
clinical examination, and storage time of the plasma samples) in any of
the cat groups with a high rate of detectable NT-proBNP plasma con-
centrations. Variables with P < .2 in the univariable regression analysis
were included in a multiple regression analysis as were BCS and sex.
Multivariable analyses were performed in a backward stepwise man-
ner, starting with all variables included in the model and then remov-
ing the variable with the highest P value until all of the remaining
variables had a P value <.05. All variables were assessed as main
effects; no interaction terms were considered in the model. The distri-
bution of the residuals was assessed for normality by inspection of
normal quantile plots. The adjusted R2 is defined as the percentage of
the total sum of squares that can be explained by the regression and
it also considers the degrees of freedom for variables added.
The optimal cutoff (combination of highest SE and SP) in NT-
proBNP concentration for identifying an abnormal POCT was investi-
gated using receiver operator characteristic (ROC) curves.
3 | RESULTS
3.1 | Study population
Of 118 examined apparently healthy cats, 18 cats were excluded. Five
of these cats had kidney disease, 5 had mild heart disease (4 cats had
cardiac disease other than HCM and 1 cat had equivocal findings con-
cerning presence of hypertrophy of the LV), 2 had severe dental disease,
2 had congenital defects (diaphragmatic hernia and peritoneal-pericardial
diaphragmatic hernia), 2 had ALT activity above the reference range, and
1 had hyperthyroidism. Of 48 examined cats with murmurs or previously
diagnosed HCM, 9 were excluded: 2 of these cats were normal, but did
not meet the breed criteria for the healthy controls, 2 had congenital
defects (ventricular septal defect and bicuspid Ao), 1 had equivocal find-
ings concerning presence of hypertrophy of the LV, 1 was in
decompensated CHF, 1 had kidney disease, 1 had hyperthyroidism, and
1 cat was treated with 4 times the normal dose of clopidogrel.
A total of 139 cats (69 males and 70 females) were included in the
study: 100 healthy controls, 32 cats with HCM without LAE and 7 HCM
cats with LAE. Three of the cats with HCMhad experienced CHF andwere
stabilizedbymedical treatment. The healthy cats consistedof 35NF, 33Bir-
man, and 32 DSH cats. The HCM cats comprised 13 breeds:
18 nonpurebred DSH, 5 Persian, 4 NF, 2 Bengal, 2 Maine Coon, 2 Ragdoll,
and 1 each of the following breeds: British Shorthair, Cornish Rex, Exotic,
Siberian, and Sphynx. Two healthy male cats were treated with deslorelin,
and 1 of the female cats with HCM without LAE was treated with
medroxyprogesterone acetate. Three of the cats with HCM without LAE
were treated with enalapril, and 3 of the stabilized CHF cats were treated
with furosemide and enalapril, of which 1 cat also received clopidogrel.
Feline characteristics, concentration of NT-proBNP, and echocardiographic
measurements of the 3 cat groups (healthy, HCM without LAE, and HCM
with LAE) are presented inTable 1 andFigure 1. Feline characteristics, echo-
cardiographic measurements, concentration of NT-proBNP, and POCT
results of the healthy control cats of the 3 different breeds are presented in
Table 2.
Blood glucose concentration was mildly increased in 11/139 cats.
However, serum fructosamine concentrations were measured and
were within normal limits in all cats, as were hematology and other
serum biochemistry variables.
3.2 | Evaluation of NT-proBNP plasma
concentration measured by ELISA
The intra-assay coefficient of variation (CV) for the feline NT-proBNP
ELISA was 5.2%-8.1%, and the interassay CVs were 7.2, 3.1, and
4.2%, respectively, for samples with mean concentrations of 57, 229,
and 639 pmol/L, respectively.
3.3 | All cats
3.3.1 | Univariable analysis
The median NT-proBNP plasma concentration was higher in male
(49 pmol/L; IQR, <24-300) than in female cats (<24 pmol/L; IQR,
<24-40; P < .0001), and higher in cats with SAM (P < .0001) than in
those that did not have SAM. The NT-proBNP concentration increased
F IGURE 1 ELISA plasma concentration of NT-proBNP versus
echocardiographic classification in the entire study population of
139 cats with and without hypertrophic cardiomyopathy. The NT-
proBNP plasma concentration measured by ELISA compared to the
echocardiographic classification are shown for normal healthy
controls (n = 100), for cats with HCM without LAE (n = 32), and cats
with HCM with LAE (n = 7). Blue line indicates 100 pmol/L, which
was the cutoff value used for evaluation of normal and abnormal
samples. Median NT-proBNP concentration for healthy was <24 (IQR
<24-31) pmol/L, HCM without LAE 253 (IQR 52-456) pmol/L, and
HCM with LAE 1496 (1007 to >1500) pmol/L differed significantly,
P < .0001. HCM, hypertrophic cardiomyopathy; IQR, interquartile
range; LAE, left atrial enlargement; NT-proBNP, N-terminal-
prohormone B-type natriuretic peptide
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with increasing IVSdinc% (R
2 = .22; P < .0001), LVPWdinc% (R
2 = .21;
P < .0001), and FS (R2 = .07; P = .002).
3.4 | Healthy cats
The median NT-proBNP concentration in the healthy cats was
<24 pmol/L in all 3 breeds with similar IQR across the breeds (Birman,
<24-39; DSH, <24-38; NF, <24-29 pmol/L). Three of the healthy con-
trols had concentrations >100 pmol/L (110, 117, and 155 pmol/L,
respectively).
3.4.1 | Univariable analysis
Median NT-proBNP concentration was higher (P = .005) in male
(25 pmol/L; IQR, <24-49) than in female cats (<24 pmol/L;
IQR, <24-26).
3.5 | Cats with HCM
Of the 39 cats with HCM, 11 cats had an NT-proBNP concentration
<100 pmol/L (range, <24-69 pmol/L).
3.5.1 | Univariable regression analysis
N-terminal-proBNP concentrations increased with increasing IVSdinc%
(R2 = .17; P = .006), percentage increase of LVFWd (LVFWdinc%;
R2 = .36; P < .0001), and LA/Ao (R2 = .17; P = .007), and with decreas-
ing SBP (R2 = .11; P = .02).
3.5.2 | Multiple regression analysis
The effect of increasing LVFWdinc% (P < .0001) on NT-proBNP con-
centration was maintained in the multiple regression analysis.
TABLE 2 Feline characteristics and echocardiographic and laboratory variables in 100 healthy cats
Group Birman Domestic Shorthair Norwegian Forest
Number 33 32 35
Sex (F/M) 21/12 14/18 22/13
Sex NF/F/NM/M 9/12/7/5 14/0/18/0 12/10/8/5
Age (years) 3.2 (1.5-7.4)a 7.1 (3.0-10.8)a 4.1 (2.1-7.2)a
Weight (kg) 3.4 (2.9-4.0)a 4.5 (4.0-5.5)b 5.4 (4.1-6.4)b
BCS normal 4-5/overweight 6-7) 21/111 14/18 14/21
HR (bpm) 160 (140-164)a 140 (132-179)a 160 (140-180)a
Murmur (yes/no) 2/31 1/31 1/34
SBP (mmHg) 124 (116-131)a 140 (136-147)b 138 (124-145)b
LA/Ao 1.1 (1.0-1.2)a 1.1 (1.0-1.2)a 1.1 (1.0-1.2)a
IVSd (mm) 3.6 (3.4-3.8)a 3.9 (3.6-4.1)b 4.0 (3.8-4.3)b
IVSd inc (%) −3.1 (−5.8 to 2.9)a 0.8 (−7.9 to 7.7)a −0.3 (−6.4 to 5.9)a
LVIDd (mm) 15.3 (13.9-15.8)a 16.3 (15.0-18.3)b 16.4 (15.7-18.0)b
LVIDdinc (%) 0.1 (−4.6 to 7.7)a 2.5 (−5.6 to 10.5)a 1.7 (−4.0 to 7.2)a
LVFWd (mm) 3.5 (3.3-3.7)a 3.8 (3.5–4.0)b 4.0 (3.6-4.2)b
LVFWdinc (%) −0.9 (−11.0 to 4.5)a −1.4 (−5.7 to 6.8)a −0.3 (−5.4 to 3.7)a
FS (%) 48 (45-56)a 51 (48-57)a 50 (46-56)a
SAM (yes/no) 0/33 0/32 0/35







Note: Within each row, values with different superscripts are statistically different (P < .017) after Bonferroni correction, and values with the same super-
script letter did not differ significantly. Superscript numbers for specific comment for number of missing values; 1 = one missing value. The median and
interquartile ranges are shown for continuous variables.
Abbreviations: BCS, body condition score; F, female; FS, fractional shortening; HR, heart rate auscultation; IVSd, interventricular septum diastole; IVSdinc%,
percentage increase in end-diastolic interventricular septal dimension; LA/Ao, left atrial-to-aortic root diameter ratio; LVFWd, left ventricular free wall
diameter in end diastole; LVFWdinc%, percentage increase in end-diastolic left ventricular free wall dimension; LVIDd, left ventricular internal diameter in
end diastole; LVIDdinc%, percentage increase in end-diastolic left ventricular internal dimension; M, male; N, neutered; NT-proBNP, N-terminal-prohormone
B-type natriuretic peptide; SAM, systolic anterior motion of the mitral valve; SBP, systolic blood pressure, basic echocardiographic data.
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Furthermore, the final model also included sex (males had higher con-
centrations, P = .002). The final model included the variables
LVFWdinc%, sex, and BW had an adjusted R
2 of .50.
Only marginal changes of the results presented above were found
after excluding the 6 cats treated with any cardiac medication (furose-
mide, enalapril, clopidogrel) from the data set, except that IVSdinc%
was no longer significantly associated with plasma concentration of
NT-proBNP.
3.6 | Evaluation of POCT NT-proBNP test results
3.6.1 | All cats
The ELISA concentration of NT-proBNP was higher in cats when the
subjective evaluation of the sample spot was darker than when the
sample spot color was equal to the control spot (P < .0001), and
higher in cats when the subjective evaluation of the sample spot was
equal to the control spot compared to when it was lighter (P < .0001)
(Figure 3). The transition interval between normal and abnormal for
the POCT was between 69 and 117 pmol/L. A ROC curve showed
that the optimal cutoff value (combination of highest SE and SP) for
ELISA NT-proBNP concentration to identify an abnormal POCT was
110 pmol/L.
3.6.2 | Healthy cats
By visual inspection of the POCT, 98/100 healthy cats were classified
as normal and 2/100 as abnormal (ELISA NT-proBNP concentrations
in these cats were 110 and 155 pmol/L, respectively; Figures 2 and 3).
By automated evaluation of the POCT, 95/100 healthy cats
were evaluated as normal and 5/100 healthy cats as abnormal
(corresponding ELISA NT-proBNP concentrations in these cats were
49, 61, 78, 88, and 155 pmol/L, respectively).
3.6.3 | Cats with HCM
By visual inspection of the POCT, 29/39 (74%) HCM cats were classified
as abnormal using the POCT (corresponding plasma NT-proBNP
F IGURE 2 Visual evaluation of point-of-care test versus
echocardiographic examination in all cats. The result of the visual
evaluation of the POCT compared to the echocardiographic
examination for normal healthy controls (n = 100), cats with HCM
without LAE (n = 32), and cats with HCM with LAE (n = 7). The
number of normal/abnormal test results for healthy controls (98/2),
HCM cats without LAE (10/22), and HCM cats with LAE (0/7).
Gray = normal test and black = abnormal test. HCM, hypertrophic
cardiomyopathy; LAE, left atrial enlargement; POCT, point-of-
care test
F IGURE 3 Classification of point of care test results based on subjective evaluation of the color. Results of the subjective evaluation of the
POCT test in 139 cats; the sample spot is located to the right and the reference spot to the left in each example. The outcome “lighter” is
indicative of a normal NT-proBNP concentration. The outcomes “equal” or “darker” are interpreted as abnormal NT-proBNP concentrations. For
the column NT-proBNP concentrations per group, the median and interquartile ranges are shown. Values with different superscripts are
statistically different (P < .0001). NT-proBNP, N-terminal-prohormone B-type natriuretic peptide; POCT, point-of-care test
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concentrations using the ELISAwere 69 pmol/L in 1 cat and >100 pmol/L
in the other 28 cats), and 10 HCM (26%) cats were classified as normal
(all had ELISA concentrations <100 pmol/L; Figures 2 and 3).
By the automated evaluation, 29/39 (74%) HCM cats were classi-
fied as abnormal using the POCT (corresponding ELISA NT-proBNP
concentrations were >100 pmol/L in 27 cats, and 61 and 69 pmol/L,
respectively, in 2 cats), and 10/39 (26%) HCM cats were classified as
normal (corresponding ELISA NT-proBNP concentrations were
<100 pmol/L in 9 cats and 168 pmol/L in 1 cat).
3.6.4 | SE and SP for detecting HCM
Using ≥100 pmol/L as a cutoff value for identifying abnormal samples,
the ELISA and visual inspection and automated evaluation of the
POCT had SE of 72 and 74% (both visual inspection and automated
evaluation) and SP of 97, 98, and 95%, respectively, for detecting
HCM when healthy cats were compared to all cats with HCM. The
ELISA and the visual inspection and automated evaluation of the
POCT had a SE of 100% and SP of 97, 98, and 95%, respectively, for
detecting HCM cats with LAE, and a SE of 69%, and SP of 97, 98, and
95% respectively, for detecting HCM cats without LAE (Figure 2)
when the specific groups were compared to healthy cats.
4 | DISCUSSION
Male cats had higher plasma NT-proBNP concentrations than did
female cats in our population of cats. The NT-proBNP concentration
in healthy cats was not affected by age, BW, BCS, or breed. In all cats,
and in the cats with HCM, the NT-proBNP concentration increased
with increasing IVSd and LVFWd. Measuring NT-proBNP using the
POCT and the ELISA tests showed similar SE and SP for detecting
HCM. The ELISA and the POCT results were abnormal in all HCM cats
with LAE, but not in all HCM cats without LAE.
Median concentration of NT-proBNP was higher in healthy male
cats than in female cats in our study. This finding contrasts with studies
in people in which the NT-proBNP concentration has been reported to
be higher in women than in men,30-32 and with studies in dogs, which
have shown ambiguous results such as no effect of sex on the NT-
proBNP concentration,33 or a higher concentration in female dogs.34,35
In previous studies in cats, sex has not been reported to significantly
influence the NT-proBNP concentration.12,14 Testosterone also may be
a factor. A suppressive effect of testosterone has been suggested to
contribute to the difference in BNP concentration between men and
women,36 and in rats, testosterone has been shown to suppress the
release of NPs.37 In our study, most of the male cats (77%) were
neutered, which may be a reason for the different results compared to
those in humans. A significant difference was found between sexes in
the healthy cat group, and the reason for this difference hopefully will
be further explored in future studies.
Although the healthy cats were from 3 genetically distant
breeds,38 with >30 cats/breed (see Table 2), no significant difference
in NT-proBNP concentration was found among the breeds, which is in
accordance with a previous study that included several different
breeds with variable and often small breed group sizes.14 This finding
is in contrast to studies in dogs, in which significant interbreed differ-
ences have been found in NT-proBNP concentrations.19,39
In the cats with HCM, lower SBP was associated with higher con-
centrations of plasma NT-proBNP. A possible explanation for this find-
ing may be that cats with more prominent HCM might have impaired
cardiac output leading to lower, but still within normal variation, SBP.40
Furthermore, NPs regulate several physiological processes, such as
arteriolar relaxation and promotion of urinary sodium excretion (natri-
uresis), which potentially might lower the SBP further.41
Left ventricular hypertrophy, LAE or both were associated with
significantly increased NT-proBNP concentrations in cats with HCM in
our study. Similar findings have been described previously in
cats,12,14,15 dogs,34 and people.42-44 The POCT had similar SE and SP
as did the ELISA for diagnosing HCM in cats, which is in agreement
with previous studies in which SE of the tests ranged between 71%-
92% and SP between 94%-100% for detecting cardiac disease.12,14,15
The test results obtained by visual inspection of the POCT were similar
to the automated evaluation. The POCT in our study had a SE of 74%
with visual inspection or automated evaluation for detecting HCM,
and the SP was slightly lower when analyzed by automated evaluation
(95%) compared to visual inspection (98%) of the NT-proBNP concen-
tration. However, our study design, with a study population consisting
of either cats with HCM or healthy cats, and excluding cats with equiv-
ocal findings concerning presence of hypertrophy of the LV, other dis-
eases than HCM, and cats with abnormal blood test results, might
have overestimated the accuracy of the test and thereby resulting in
higher SE and SP for the ELISA and the POCT test than if the test had
been used in the general feline population. Differences in SE (65%-
84%) and SP (83%-100%) in POCT results in previous studies of
cats9,11 may be explained by different study populations including cats
with different cardiac diseases and different disease severities. In our
study, the observed echocardiographic measurements were related to
BW-dependent expected values both in the healthy cats and in the
cats with HCM.27 Evaluations of the accuracy of the POCT for
assessing HCM in cats categorized using echocardiographic measure-
ments adjusted for BW have not been published previously. In our
study, none of the HCM cats with LAE had a normal POCT result,
whereas 31% of the HCM cats without LAE had a normal POCT result
(see Figure 2). The POCT showed a higher false-negative rate than true
positive rate, which implies that a cat with a normal POCT may need
further evaluation by echocardiography to exclude mild HCM. Similar
results have been reported previously for both the POCT and the
quantitative ELISA in cats with cardiac disease.9,11,14
Evaluation of the color of the sample spot at visual inspection of
the POCT (see Figure 3) showed that NT-proBNP plasma concentra-
tion differed significantly among the 3 POCT groups: lighter (normal),
equal (mildly abnormal) and darker (abnormal). This finding may
increase the value of the POCT for the assessment of whether cardiac
disease is likely or not, because the results are readily available and
give an estimate of the NT-proBNP concentration.
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In our study, cats with severe dental disease obvious on clinical
examination were excluded because periodontitis is an inflammatory
disease that causes pain, gingival bleeding, and may impact overall
health.45 In people, patients with periodontitis have been shown to
have higher serum NT-proBNP concentrations than individuals with-
out periodontitis and the greater the extent of periodontal destruc-
tion, the higher the concentration of NT-proBNP in serum.46
4.1 | Study Limitations
Blood was collected only once from each cat. Therefore, biological varia-
tion in NT-proBNP concentration within an individual cat could not be
evaluated. Studies have indicated a high biological variation for NT-proBNP
concentrations in cats, dogs, and humans, and this variability may affect
the SE and SP.47-49 The healthy control cats were examined in the morning
to decrease the effect of diurnal variation among the cats included in the
study. Cats with HCM were not examined at a standardized time of day
because of the clinical condition of the cat and for practical reasons.
Plasma samples were stored at −80C up to 4 years before
batched analyses were performed, but storage time was not shown to
be associated with the NT-proBNP plasma concentration. Further-
more, previous studies have shown that NT-proBNP concentrations
are stable at the freezing temperatures used in our study.50-52 It thus
is unlikely that storage had any major effect on the results.
The POCT becomes abnormal within a transition interval rather
than a set cutoff value, which is a limitation. In our study, the transi-
tion interval was found to between 69 and 117 pmol/L, which is
slightly lower than a previous study in which the transition occurred
between 108 and 122 pmol/L9 but different from another study in
which the transition interval was between 150 and 200 pmol/L.11
However, the SE and the SP for the ELISA and the POCT were similar,
therefore the POCT results seem reliable.
In our study, the cats with HCM without LAE generally were mildly
affected and few cats had HCMwith LAE. Furthermore, a few of the cats
included were treated with deslorelin, medroxyprogesterone acetate, or
cardiac medications. Three of the HCM cats with LAE were on medical
treatment for previous CHF, and plasma concentrations of NT-proBNP in
cats treated for CHFmay decrease after stabilization of CHF.53
The design of our study, using selected inclusion and exclusion
criteria, may have influenced the accuracy of the test and thereby
overestimated SE and SP. Our study was intended as an explorative
study, and further research in a mixed cat population is warranted.
Although no differences in NT-proBNP concentration were found
among the 3 genetically distant breeds in the study, differences
among other breeds cannot be excluded.
5 | CONCLUSIONS
Male cats had higher plasma NT-proBNP concentrations than did
female cats, but other characteristics, such as breed, age, BW, and
BCS, were not associated with plasma NT-proBNP concentration.
The POCT gave a quick semiquantitative estimate of NT-proBNP
concentration, with similar SE and SP to those found using the quanti-
tative ELISA test for detecting HCM in cats. Both tests could identify
all HCM cats with LAE but not all HCM cats without LAE.
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